Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-23
2007-10-23
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C514S015800, C514S016700, C514S017400, C514S018700, C514S019300, C514S885000, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000, C530S331000, C530S332000, C424S810000
Reexamination Certificate
active
10126223
ABSTRACT:
Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide-based inhibitors of cathepsin S are also described.
REFERENCES:
patent: 5422359 (1995-06-01), Ando et al.
patent: 5501969 (1996-03-01), Hastings et al.
patent: 5510333 (1996-04-01), Angelastro et al.
patent: 5559028 (1996-09-01), Humphreys
patent: WO 94/04557 (1994-03-01), None
patent: WO 95/23222 (1995-08-01), None
patent: WO 96/30353 (1996-10-01), None
Valderrama, R. et al. J. Neurological Sciences [1987] 82(1-3):133-143.
McDonald, JK et al. Arch. Biochem. Biophys. [1993] 305(1):1-8.
Takei, Y et al. Transplantation [1990] 50(1):14-20.
Eisenbarth, G et al. New Eng. J. Med. [1978] 298(2):92-94.
E.A. Hughes et al. “The Protease Inhibitor, N-Acetyl-L-Leucyl-L-Leucyl-L-Norleucinal, Decreases the Pool of Major Histocompatibility Complex Class I-binding Peptides and Inhibits Peptide Trimming in the Endoplasmic Reticulum”J. Exp. Med. 183:1569-1578 (1996).
S. Petanceska et al.. “Expression of Rat Cathepsin S in Phagocytic Cells”The Journal of Biological Chemistry271 (8):4403-4409 (1996).
R.J. Riese et al. “Essential Role for Cathepsin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading”Immunity4:357-366 (1996).
E. Carmona et al. “Potency and Selectivity of the Cathepsin L Propeptide as an Inhibitor of Cysteine Proteases”Biochemistry35:8149-8157 (1996).
H.U. Demuth et al. “N-peptidyl, O-acyl hydroxamates: comparison of the selective inhibition of serine and cysteine proteinases”Biochimica et Biophysica Acta1295:179-186 (1996).
D. Brömme et al. “Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors”Biochem J. 315:85-89 (1996).
P. Morton et al. “Delivery of Nascent MHC Class II-Invariant Chain Complexes to Lysosomal Compartments and Proteolysis of Invariant Chain by Cysteine Proteases Precedes Peptide Binding in B-Lymphoblastoid Cells”The Journal of Immunology154:137-150 (1995).
J.T. Palmer et al. “Vinyl Sulfones as Mechanism-Based Cysteine Protease Inhibitors”J. Med. Chem. 38:3193-3196 (1995).
K. Okamoto et al. “The Characterization of the Inhibition of Mature Cysteine Proteases By Their Proregions”J. of Cellular Biochemistry Suppl. 0(1913):254 (1995).
B. J. Gour-Salin “E-64 Analogs as Inhibitors of Cathepsin L and Cathepsin S: Importance of the S2-P2Interactions for Potency and Selectivity”Bioorganic Chemistry22:227-241 (1994).
V., Turk et al. “Human Cysteine Proteinases and Their Inhibitors, Stefins and Cystatins” inBiological Functions of Proteases and Inhibitors, N. Katunuma et al., eds. Japanese Scientific Press, Tokyo Japan, Chap. 4:47-59 (1994).
H. Kirschke et al. “Cathepsin S and Related Lysosomal Endopeptidases”Cysteine PeptidasesAcademic Press, Inc. 34:500-511 (1994).
G.P. Shi et al. “Human Cathepsin S: Chromosomal Localization, Gene Structure, and Tissue Distribution”The Journal of Biological Chemistry269(15):11530-11536 (1994).
D. Brömme et al. “Potent Inactivation of Cathepsins S and L by Peptidyl (Acyloxy)methyl Ketones”Biol. Chem. Hoppe-Seyler375:343-347 (1994).
D. Brömme et al, “N-Peptidyl-o-carbamoyl amino acid hydroxamates: Irreversible inhibitors for the study of the S2' specificity of cysteine proteinases”FEBS 12414322(3):211-214 (1993).
E. Shaw et al. “The affinity-labelling of cathepsin S with peptidyl diazomethyl ketones: Comparison with the inhibition of cathepsin L and calpain”FEBS 13268334(3):340-342 (1993).
N.K. Ahmed et al. “Peptidyl Fluoromethyl Ketones as Inhibitors of Cathepsin B: Implication for Treatment of Rheumatoid Arthritis”Biochemical Pharmacology44(6):1201-1207 (1992).
D. Brömme et al. “The Specificity of Bovine Spleen Cathepsin S: A comparison with rat liver cathepsins L and B”Biochem J. 264:475-481 (1989).
J. Pohl et al. “Chromophoric and Fluorophoric Peptide Substrates Cleaved through the Dipeptidyl Carboxypeptidase Activity of Cathepsin B”Analytical Biochemistry165:96-101 (1987).
Lenarcic et al., “Pig leukocyte cysteine proteinase inhibitor (PLCPI), a new member of the stefin family”FEBS 13443336(2):289-292 (1993).
Hanzlik et al., Vinylogous Amino Acid Esters: A New Class of Inactivators for Thiol Proteases,Journal of Medicinal Chemistry, 27(6):711-712 (1984).
Bromme et al., “High level expression and crystallization of recombinant human cathepsin S”, Protein Science 5: 789-791 (1996).
Turk et al., “Kinetics of inhibition of bovine cathepsin S by bovine stefin B”, FEBS Letters 339 155-159 (1994).
Kirschke et al., “Cathepsin S The cysteine proteinase from bovine lymphoid tissue is distinct from cathepsin L (EC 3.4.22.15)”, Biochem. J. 240, 455-459 (1986).
Blum et al., “Role for intracellular proteases in the processing and transport of class II HLA antigens”, Proc. Natl. Acad. Sci., vol. 85 pp. 3975-3979, (1988).
Chapman et al., “The Role of Thiol Proteases in Tissue Injury and Remodeling”, Am. J. Respir. Crit Care Med. vol. 150, pp. S155-S159, (1994).
Maciewicz et al., “Susceptiblity of the cartilage collagens types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L”, FEBS Letters, vol. 269, No. 1 189-193 (1990).
Esser et al., “The Effects of Fluoromethyl Ketone Inhibitors of Cathepsin B on Adjuvant Induced Arthritis”, The Journal of rheumatology 20:7 pp. 1176-1183, (1993).
Esser et al., “Cysteine Proteinase Inhibitors Decrease Articular Cartilage and Bone Destruction In Chronic Inflammatory Arthritis”, Arthritis & Rheumatism, vol. 37, No. 2, pp. 236-247 (1994).
Ahmed et al., “Peptidyl Fluoromethyl Ketones as Inhibitors of Cathepsin B”, Biochemical Pharmacology, vol. 44, No. 6 pp. 1201-1207, (1992).
Kregar et al., “Bovine Intracellular Cysteine Proteinases”, Acta Biol. Med. Germ., Band 40, Seite 1433-1438 (1981).
Bogyo Matthew S.
Bryant Paula R.
Chapman Harold A.
Ploegh Hidde L.
Riese Richard J.
Brigham & Women's Hospital Inc.
Chan Christina
Massachusetts Institute of Technology
Ropes & Gray LLP
VanderVegt F. Pierre
LandOfFree
Suppression of immune response via inhibition of cathepsin S does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Suppression of immune response via inhibition of cathepsin S, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Suppression of immune response via inhibition of cathepsin S will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3864327